S. Stilgenbauer

2.2k total citations
19 papers, 71 citations indexed

About

S. Stilgenbauer is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, S. Stilgenbauer has authored 19 papers receiving a total of 71 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in S. Stilgenbauer's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). S. Stilgenbauer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). S. Stilgenbauer collaborates with scholars based in Germany, Denmark and United States. S. Stilgenbauer's co-authors include Michael Hallek, M. Hensel, Eva Lengfelder, Robert Busch, Lorenz Trümper, Peter Dreger, Dirk Winkler, Ulrich Jäger, Alexander Kröber and H. Döhner and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Immunology.

In The Last Decade

S. Stilgenbauer

18 papers receiving 70 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Stilgenbauer Germany	5	56	50	27	18	10	19	71
Yufu Lin China	3	50 0.9×	35 0.7×	28 1.0×	22 1.2×	18 1.8×	10	81
Éric Durot France	6	65 1.2×	74 1.5×	22 0.8×	21 1.2×	16 1.6×	26	92
Tommi Salmi United States	5	86 1.5×	75 1.5×	23 0.9×	17 0.9×	24 2.4×	11	96
Alfonso Martín Carnicero Spain	4	41 0.7×	37 0.7×	21 0.8×	10 0.6×	11 1.1×	10	69
Ganna Usenko Ukraine	3	71 1.3×	61 1.2×	22 0.8×	18 1.0×	30 3.0×	14	84
Lauren E. Strelec United States	5	30 0.5×	68 1.4×	18 0.7×	47 2.6×	7 0.7×	11	81
Iryna Kriachok Ukraine	4	86 1.5×	70 1.4×	31 1.1×	17 0.9×	31 3.1×	10	93
M Asuncion Echeveste Spain	3	61 1.1×	46 0.9×	16 0.6×	8 0.4×	29 2.9×	4	75
Sabrina Kless Germany	3	76 1.4×	61 1.2×	34 1.3×	11 0.6×	5 0.5×	4	77
Elżbieta Iskierka‐Jazdzewska Poland	7	71 1.3×	84 1.7×	26 1.0×	36 2.0×	21 2.1×	25	110

Countries citing papers authored by S. Stilgenbauer

Since Specialization

Citations

This map shows the geographic impact of S. Stilgenbauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Stilgenbauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Stilgenbauer more than expected).

Fields of papers citing papers by S. Stilgenbauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Stilgenbauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Stilgenbauer. The network helps show where S. Stilgenbauer may publish in the future.

Co-authorship network of co-authors of S. Stilgenbauer

This figure shows the co-authorship network connecting the top 25 collaborators of S. Stilgenbauer. A scholar is included among the top collaborators of S. Stilgenbauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Stilgenbauer. S. Stilgenbauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Seymour, John F., Ricardo Parrondo, Meghan C. Thompson, et al.. (2025). 144 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB‐16673 IN RELAPSED/REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE ONGOING PHASE 1 CaDAnCe‐101 STUDY. Hematological Oncology. 43(S3).

Fink, Anna‐Maria, Eugen Tausch, Matthias Ritgen, et al.. (2022). S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY. HemaSphere. 6. 49–50. 2 indexed citations

Cramer, Paula, Moritz Fürstenau, Eugen Tausch, et al.. (2022). P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS. HemaSphere. 6. 539–540. 1 indexed citations

Al‐Sawaf, Othman, Sandra Robrecht, Anna‐Maria Fink, et al.. (2021). THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION. Hematological Oncology. 39(S2). 3 indexed citations

Unterhalt, Michael, S. Stilgenbauer, Kai Hübel, et al.. (2019). AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION‐FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematological Oncology. 37(S2). 43–44. 7 indexed citations

Bahlo, Jasmin, et al.. (2017). The GAIA (CLL13) trial – an international, randomized, four-arm study for first line treatment of physically fit CLL patients without del17p or TP53 mutation. 4(5). 1 indexed citations

Hillmen, Peter, Christelle Ferrá, José A. García‐Marco, et al.. (2016). Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. Haematologica. 101. 433–433. 2 indexed citations

Goede, Valentin, Raymonde Busch, Jasmin Bahlo, et al.. (2015). Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leukemia & lymphoma. 57(3). 596–603. 3 indexed citations

Tausch, Eugen, R. Schlenk, Peter Hillmen, et al.. (2014). SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). Haematologica. 99. 522–523. 1 indexed citations

10.

Hagn, Magdalena, Sue Blackwell, Thamara Beyer, et al.. (2014). B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. International Immunology. 26(7). 383–395. 13 indexed citations

11.

Sharman, Jeffrey P., Steven Coutré, Richard R. Furman, et al.. (2014). PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Leukemia Research. 38. S44–S45. 2 indexed citations

12.

Langerbeins, Petra, Carmen D. Schweighofer, Anna Maria Fink, et al.. (2014). More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group. Kölner Universitäts PublikationsServer (Universität zu Köln). 1 indexed citations

13.

Kluin‐Nelemans, Hanneke C., Eva Hoster, Olivier Hermine, et al.. (2011). R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN: FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA. Annals of Oncology. 22. 86–86. 4 indexed citations

14.

Dreyling, Martin, Eva Hoster, Ursula Vehling‐Kaiser, et al.. (2011). Rituximab maintenance after combined immuno-chemotherapy significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. Data Archiving and Networked Services (DANS). 34. 200–201. 2 indexed citations

15.

Winkler, Dirk, Manuela Zucknick, K. Schulze, et al.. (2010). Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica. 95(11). 1880–1888. 3 indexed citations

16.

Wierda, William G., Thomas J. Kipps, Laimonas Griškevičius, et al.. (2010). Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 28(15_suppl). 6520–6520. 1 indexed citations

17.

Elter, Thomas, C.‐M. Wendtner, S. Stilgenbauer, et al.. (2008). Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group. Journal of Clinical Oncology. 26(15_suppl). 7053–7053. 2 indexed citations

18.

Stilgenbauer, S., Alexander Kröber, Dirk Winkler, et al.. (2005). Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG). mediaTUM (Technical University of Munich). 18 indexed citations

19.

Wolff, Daniel, Beate Steiner, S. Stilgenbauer, et al.. (2004). Treatment with campath‐1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD. European Journal Of Haematology. 72(2). 145–148. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact